» Articles » PMID: 39399742

Temporal Dynamics of Hepatitis B Infection and Relation of Childhood Vaccination Program in Türkiye: A Longitudinal Study

Overview
Date 2024 Oct 14
PMID 39399742
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Hepatitis B is a significant infectious disease on a global scale. The implementation of vaccination programs and other preventive measures (e.g., serologic screening of blood donors) leads to lower rates of new infections with the hepatitis B virus. This study aimed to investigate and compare the evolution of hepatitis B incidence, prevalence and mortality rates along with vaccination rates in Türkiye and worldwide between 1990 and 2019.

Materials And Methods: The study analyzed open datasets (the Global Burden of Disease and Our World in Data) using descriptive and joinpoint regression analysis to uncover substantial declines in hepatitis B rates from 1990 to 2019, both in Türkiye and globally.

Results: The average annual percentage change (AAPC) for incidence rates was -1.81 in Türkiye and -1.481 in the global cohort. For prevalence, the AAPC was -2.5244 in Türkiye and -1.4104 globally.

Conclusion: The vaccination rates increased over time and remained at 95% since 2009, suggesting that vaccination efforts effectively reduced the risk of hepatitis B infection among children. This study provided important perspectives for assessing Türkiye's performance in this field and guiding future strategies.

References
1.
Kim H, Fay M, Yu B, Barrett M, Feuer E . Comparability of segmented line regression models. Biometrics. 2004; 60(4):1005-14. DOI: 10.1111/j.0006-341X.2004.00256.x. View

2.
Alberts C, Clifford G, Georges D, Negro F, Lesi O, Hutin Y . Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022; 7(8):724-735. PMC: 9259503. DOI: 10.1016/S2468-1253(22)00050-4. View

3.
. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

4.
. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec. 2017; 92(27):369-92. View

5.
Pattyn J, Hendrickx G, Vorsters A, Van Damme P . Hepatitis B Vaccines. J Infect Dis. 2021; 224(12 Suppl 2):S343-S351. PMC: 8482019. DOI: 10.1093/infdis/jiaa668. View